{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:50:23Z","timestamp":1785790223919,"version":"3.56.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    A 78-year-old woman with medullary thyroid carcinoma (MTC) demonstrated persistently elevated serum calcitonin despite prior surgery and radiotherapy.\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-octreotide imaging failed to detect skeletal metastases, while\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAPI PET\/CT revealed extensive skeletal involvement. Biochemical markers were disproportionately low relative to disease burden, consistent with a low-secretory MTC. This case highlights the limitations of SSTR-targeted imaging in MTC and underscores the diagnostic superiority of FAP-targeted imaging.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006450","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:00:13Z","timestamp":1775671213000},"page":"e797-e798","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Widespread Skeletal Metastases in Medullary Thyroid Carcinoma"],"prefix":"10.1097","volume":"51","author":[{"given":"Fatemeh","family":"Taheri","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center"},{"name":"Student Research Committee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin Saber","family":"Tanha","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"},{"name":"Student Research Committee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robabeh Beygom","family":"Aboutorabi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Ghaem Hospital, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Rostami","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"},{"name":"Student Research Committee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-2251","authenticated-orcid":false,"given":"Emran","family":"Askari","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.21037\/gs-24-292","article-title":"Diagnostic challenges in calcitonin negative medullary thyroid carcinoma: a systematic review of 101 cases","volume":"13","author":"Abaalkhail","year":"2024","journal-title":"Gland Surg"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1210\/jc.2014-3095","article-title":"Medullary thyroid cancer with undetectable serum calcitonin","volume":"100","author":"Brutsaert","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260803","first-page":"1413","article-title":"In vivo somatostatin receptor imaging in medullary thyroid carcinoma","volume":"76","author":"Kwekkeboom","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1089\/thy.2023.0008","article-title":"Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC positron emission tomography\/computed tomography imaging for the follow-up surveillance of patients with medullary thyroid cancer","volume":"33","author":"Ballal","year":"2023","journal-title":"Thyroid"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-24-0897","article-title":"CTR-FAPI PET enables precision management of medullary thyroid carcinoma","volume":"15","author":"Kong","year":"2025","journal-title":"Cancer Discov"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1097\/RLU.0000000000005605","article-title":"Application of 99mTc-FAPI-46 imaging in a patient with medullary thyroid carcinoma: navigating the landscape of novel radiotracers","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1097\/RLU.0000000000005469","article-title":"Variable tracer avidity and interlesional heterogeneity on 18F-FDG, 68Ga-DOTATATE, and 68Ga-DOTA-FAPi-04 PET\/CT imaging in a single individual patient with progressive metastatic medullary thyroid carcinoma","volume":"49","author":"Edamadaka","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R9-20260803","article-title":"FAPI-based theranostics in medullary thyroid cancer: a viable alternative when somatostatin receptor-based theranostics show limited efficacy\u2014a clinical experience","author":"Saber Tanha","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/RLU.0000000000005723","article-title":"Combination therapy with 177Lu-FAPI-2286 and tyrosine kinase inhibitor: a novel approach for treating metastatic medullary thyroid carcinoma","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1097\/RLU.0000000000004051","article-title":"Fibroblast activation protein inhibitor imaging and therapy in a patient with multiple endocrine neoplasia type 2A syndrome","volume":"47","author":"Barashki","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:02:00Z","timestamp":1785787320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006450"}},"subtitle":["Diagnostic Superiority of 68Ga-FAPI PET\/CT Over Somatostatin Receptor-Targeted Imaging"],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006450","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"2025-12-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}